Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of oral larotrectinib in children with advanced solid tumors or primary CNS tumors
CTR20190626Phase 2Completed
- Sponsor
- Bayer
- Start
- Apr 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of larotrectinib in TRK fusion cancer (NTRK), central nervous system primary tumor, congenital fibrosarcoma (CFS), mesoblastic nephroma (CMN), secretory breast carcinoma (SBC), sponsored by Bayer. Started Apr 2020; status: completed.
02
Drugs
larotrectinib
03
Conditions
TRK fusion cancer (NTRK)central nervous system primary tumorcongenital fibrosarcoma (CFS)mesoblastic nephroma (CMN)secretory breast carcinoma (SBC)
Beyond the preview
Go deeper on CTR20190626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190626.